Table 1 Patient characteristics
From: Prognostic role of serum p53 antibodies in lung cancer
| Ā | Lung cancer patients | Controls |
|---|---|---|
Age (years) | Ā | Ā |
ā¤60 | 47 (23.4%) | 27 (50.0%) |
>60 | 154 (76.6%) | 27 (50.0%) |
Total | 201 | 54 |
Sex | Ā | Ā |
Male | 157 (78.1%) | 27 (50.0%) |
Female | 44 (21.9%) | 27 (50.0%) |
Total | 201 | 54 |
Histological type | Ā | Ā |
NSCLC | Ā | Ā |
Adenocarcinoma | 79 (39.3%) | Ā |
Squamous cell carcinoma | 70 (34.8%) | Ā |
Bronchioloalveolar carcinoma | 6 (3.0%) | Ā |
Large cell carcinoma | 5 (2.5%) | Ā |
Anaplastic carcinoma | 19 (9.4%) | Ā |
Mixed carcinoma | 9 (4.5%) | Ā |
SCLC | 13 (6.5%) | Ā |
Total | 201 | Ā |
NSCLC stage | Ā | Ā |
I | 68 (36.2%) | Ā |
II | 24 (12.8%) | Ā |
III | 40 (21.3%) | Ā |
IV | 45 (23.9%) | Ā |
Missing | 11 (5.9%) | Ā |
Total | 188 | Ā |
NSCLC grade | Ā | Ā |
G1 | 4 (2.1%) | Ā |
G2 | 57 (30.3%) | Ā |
G3 | 72 (38.3%) | Ā |
Missing | 55 (29.3%) | Ā |
Total | 188 | Ā |